2745 A comparison of overall survival (OS) between 40 and 50mg/m2 pegylated liposomal doxorubicin (PLD) in recurrent epithelial ovarian cancer (OC) patients (pts): Propensity score (ProS) matched analysis of real world data. (September 2015)